Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau

Journal of Alzheimer's Disease : JAD
Ziyi LiuIkuo Tooyama

Abstract

Cost-effective and feasible methods for early diagnosis of Alzheimer's disease (AD) are needed. We present two methods to measure AD-related biomarkers simultaneously from one nasal smear for the purpose of diagnosing AD. Japanese men and women aged 63-85 years old were recruited in 2015-2016 for this case-control study. A total of 25 AD cases and 25 controls (22 men and 28 women) participated in this research. Nasal smears were collected from the common nasal meatus, inferior concha, middle nasal meatus, and olfactory cleft, and the proteins in the samples were analyzed by two methods, which we named PGD (Pre-treatment with guanidine- n-Dodecyl-beta-D-maltoside solution) method 1 (PGD-I) and 2 (PGD-II). The PGD-I method measured total tau and amyloid-β (Aβ)42, but no differences in median levels of total tau and Aβ42 between AD cases and controls were found in any of the nasal locations. The PGD-II method measured Aβ42, total tau, and phosphorylated tau, but levels of Aβ40 in all nasal locations of both groups were near zero. Median levels of phosphorylated tau to total tau (p-tau/t-tau) ratios in the middle nasal meatus and in the olfactory cleft were significantly higher in AD cases than in controls, and could significantly ...Continue Reading

References

Jul 1, 1992·Neurobiology of Aging·R G Struble, H B Clark
Jan 1, 1996·Acta Neurologica Scandinavica. Supplementum·H Braak, E Braak
Aug 9, 2008·Journal of Clinical Epidemiology·Shrikant I BangdiwalaAndrés Villaveces
May 26, 2009·Brain Research Reviews·Fei SongPerminder Sachdev
Jul 9, 2009·Journal of Alzheimer's Disease : JAD·Sergio CammarataMassimo Tabaton
May 4, 2010·Annals of Neurology·Steven E ArnoldJohn Q Trojanowski
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Keith A JohnsonWilliam E Klunk
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Nov 28, 2012·Nature Reviews. Neurology·Reisa A SperlingKeith A Johnson
Apr 23, 2013·Neuroscience Research·Naoko KameshimaIkuo Tooyama
Mar 28, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anja Hviid SimonsenGunhild Waldemar
Mar 28, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Sanna-Kaisa HerukkaGunhild Waldemar
Aug 11, 2017·Alzheimer's Research & Therapy·Paul S AisenBruno Dubois

❮ Previous
Next ❯

Citations

Mar 23, 2019·Scientific Reports·Young Hyo KimSeong Hye Choi
Apr 13, 2021·Annals of Nuclear Medicine·Anish KapadiaUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Methods Mentioned

BETA
structural magnetic resonance
transgenic
Protein
ELISA
Protein Assay
biopsies

Software Mentioned

GraphPad Prism
SAS

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.